Q-omics provides the consensus-scored TMEM140 profile across patient tissues and cancer cell-line models. TMEM140 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM140 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TMEM140 RNA expression shows 16,806 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where TMEM140 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM140 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM140 survival associations across molecular data types. TMEM140 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM140 RNA expression–survival associations across cancer types. High TMEM140 expression shows unfavorable associations in LUSC and LGG, but favorable associations in KIRC, HNSC, KIRP and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM140 RNA expression.
This table summarizes TMEM140 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM140. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM140 shows lower tumor expression in COAD, LUAD and LUSC and higher tumor expression in KIRC, HNSC and KIRP. The KIRC box plot shows higher TMEM140 RNA expression in tumor versus normal tissue (log2 FC = +1.940, t-test p < 0.001).
This table shows molecular features associated with TMEM140 in patient tissues and cancer cell lines. In patient samples, TMEM140 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM140 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
